Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia
Fig 6
CAM expands the CD11b+Gr-1+ cell population via the STAT3-Bv8 axis.
(A and B) Representative immunoblotting of Bv8 (A) and phosphorylated (p)-STAT3 (B). Beta-actin and total (t) STAT3 were used as loading controls. Relative band intensities ware quantified by densitometry. (C and D) Representative two-parameter dot plots of CD11b+Gr-1+ cells in the spleen (C) and lungs (D) sorted from mice intraperitoneally treated with vehicle or CAM (100 mg/day) daily for three consecutive days. Mice were intraperitoneally injected with an anti-Bv8 antibody (5 mg/kg) or control IgG at 4 days and 1 day before CAM treatment and daily for three consecutive days during CAM treatment (n = 4 per group). (E and F) Representative two-parameter dot plots of CD11b+Gr-1+ cells in the spleen (E) and lungs (F) sorted from poly(I:C)-treated Stat3flox/flox/Mx1-Cre (Stat3ΔMx1) mice and control Stat3flox/flox mice that were intraperitoneally treated with vehicle or CAM (100 mg/day) daily for three consecutive days (n = 4 per group). (G) Bv8 (Prok2) mRNA expression in CD11b+Gr-1+ cells sorted from Stat3ΔMx1 mice and control Stat3flox/flox mice (n = 4 per group). Data are presented as the mean ± SEM. ***p < 0.001 by the Mann–Whitney U-test.